Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 11:31:01 +0200Fri, 28 Jun 2024 12:00:45 +0200Summary of opinion: Vabysmo, 27/06/2024 Positivehttps://www.ema.europa.eu/en/medicines/human/variation/vabysmoSummary of opinion: Vabysmo, 27/06/2024 Positivehttps://www.ema.europa.eu/en/medicines/human/variation/vabysmoFri, 28 Jun 2024 12:00:45 +0200Human medicineHuman medicines European public assessment report (EPAR): Vabysmo, faricimab, Date of authorisation: 15/09/2022, Revision: 2, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/vabysmoHuman medicines European public assessment report (EPAR): Vabysmo, faricimab, Date of authorisation: 15/09/2022, Revision: 2, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/vabysmoThu, 21 Mar 2024 15:03:00 +0100Human medicineVabysmo : EPAR - All Authorised Presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/ema-other-h-5642-aa_en.pdfVabysmo : EPAR - All Authorised Presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/ema-other-h-5642-aa_en.pdfThu, 13 Oct 2022 11:55:00 +0200Human medicine